Read the full press release on the Gedea Biotech AB website: Link
PRESS RELEASE: clinical study for our lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV), completes recruitment!
The randomized double-blind placebo-controlled study is designed to confirm the safety and efficacy of pHyph and is coordinated by Nottingham University Hospitals NHS Trust across 6 UK and 4 Swedish sites. Results from the first treatment period (day 0-7) are expected in Q2 and for the follow-up period in Q3. This would put us in a strong position to achieve #CEmarking by the end of the year.
Tell us more. Solutions from Link2Trials go one step further. Let us know your goals